Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 29;218(9):e20200962. doi: 10.1084/jem.20200962

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Fukuda et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure S3. — The role of DNA sensing, IFNAR, and CXCL10 in AIM2-deficient DC vaccine with ACT on tumor, TdLN, and spleen in the B16F10 model.(A and B) Flow cytometry analysis of the numbers of PMELs, CD8⁺ T cells (A), and CD4⁺ T cells among 10⁴ live singlet cells and percentages of FoxP3⁺ cells in CD4⁺ T cells (B) in the TdLN and spleen of B16F10 mice treated with ACT + WT or Aim2^−/− DC-gp100 and intratumoral administration of DNase I or PBS (n = 9). (C–E) Flow cytometry analysis of the percentage of FoxP3⁻ cells in total CD4⁺ T cells, numbers of CD103⁺ and CD11b⁺ DCs among 10⁴ live singlet cells in the tumor (C), numbers of PMELs, CD8⁺ T cells (D), and CD4⁺ T cells among 10⁴ live singlet cells and percentages of FoxP3⁺ cells in CD4⁺ T cells (E) in the TdLN and spleen of B16F10 mice treated with ACT + WT, Aim2^−/−, Aim2^−/−Ifnar^−/−, or Aim2^−/−Cxcl10^−/− DC-gp100 (n = 10 or 11). Data are shown as mean ± SEM and are pooled from four (A and B) or three (C–E) independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; one-way ANOVA with Tukey’s multiple-comparisons test (A–E).